Sugi Predict

Sugi Predict / Compounds / SCHEMBL1366451

SCHEMBL1366451

SCHEMBL1366451

O=C(CCCCCN1c2ccccc2C=Cc2ccccc21)NO

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 14/20 0.79
▸ HDAC1 Q13547 14/20 0.65
▸ HDAC6 Q9UBN7 13/20 0.65
▸ HDAC3 O15379 12/20 0.65
▸ HDAC2 Q92769 12/20 0.65
▸ HDAC4 P56524 11/20 0.65
▸ HDAC7 Q8WUI4 11/20 0.65
▸ HDAC10 Q969S8 11/20 0.65
▸ HDAC11 Q96DB2 11/20 0.65
▸ HDAC9 Q9UKV0 11/20 0.65
▸ HDAC5 Q9UQL6 11/20 0.65
▸ TUBB4A P04350 5/20 0.57
▸ TUBB P07437 5/20 0.57
▸ TUBA3C P0DPH7 5/20 0.57
▸ TUBA1B P68363 5/20 0.57
▸ TUBA4A P68366 5/20 0.57
▸ TUBB4B P68371 5/20 0.57
▸ TUBB3 Q13509 5/20 0.57
▸ TUBB2A Q13885 5/20 0.57
▸ TUBB8 Q3ZCM7 5/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2143965 1.00 HDAC8 (0.79) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL2143907 0.98 HDAC8 (0.76) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL1366765 0.94 HDAC8 (0.70) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL5862632 0.83 HDAC8 (0.56) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL2143960 0.82 HDAC8 (0.60) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL1366463 0.82 HDAC8 (0.60) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL1368072 0.81 HDAC6 (0.69) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL17425292 0.80 HDAC8 (0.57) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL1366876 0.79 HDAC8 (0.55) HDAC8HDAC1HDAC6HDAC3MTNR1A
SCHEMBL14862921 0.79 HDAC8 (1.00) HDAC8HDAC1HDAC6HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase FMR LLC 2017-01-05 — — US disclosed
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase FMR LLC 2017-01-05 — — US disclosed
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase FMR LLC 2017-01-05 — — US disclosed
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors FMR LLC 2016-08-04 — — US disclosed
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors FMR LLC 2016-08-04 — — US disclosed
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors FMR LLC 2016-08-04 — — US disclosed
EP-2966078-A2 Inhibitors of histone deacetylase MethylGene Inc. (CA) 2016-01-13 — — EP disclosed
EP-2966078-A2 Inhibitors of histone deacetylase MethylGene Inc. (CA) 2016-01-13 — — EP disclosed
US-9193749-B2 Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors FORUM PHARMACEUTICALS, INC. (US) 2015-11-24 — — US disclosed
US-9193749-B2 Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors FORUM PHARMACEUTICALS, INC. (US) 2015-11-24 — — US disclosed
US-20110288070-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-11-24 — — US disclosed
US-20110288070-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-11-24 — — US disclosed
US-20110196147-A1 INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-08-11 — — US disclosed
US-20110196147-A1 INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-08-11 — — US disclosed
US-20110196147-A1 INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-08-11 — — US disclosed
EP-2343286-A1 Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase Methylgene, Inc. (CA) 2011-07-13 — — EP disclosed
EP-2343286-A1 Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase Methylgene, Inc. (CA) 2011-07-13 — — EP disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288070-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC5, HDAC2 HDAC8 7/4885HDAC1 1/4885HDAC6 9/4885
US-20080207590-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC11 HDAC8 9/4885HDAC1 1/4885HDAC6 11/4885
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase HDAC5, KAT2A, HDAC1 HDAC8 8/4885HDAC1 3/4885HDAC6 11/4885
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors HDAC1, HDAC2, HDAC4 HDAC8 8/4885HDAC1 1/4885HDAC6 9/4885
US-20110196147-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC5, HDAC11 HDAC8 9/4885HDAC1 1/4885HDAC6 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.